癫痫药物市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00024323
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 139
Buy Now

【研究报告】癫痫药物市场规模预计将从2022年的77.685亿美元增至2030年的107.0548亿美元;据估计,从 2022 年到 2030 年,该市场的复合年增长率将达到 4.1%。
市场洞察和分析师观点:
癫痫是一种神经系统疾病,可导致癫痫发作并影响全球数百万人。癫痫药物也称为抗癫痫药物(AED),通常用于治疗癫痫,因为它有助于更好地管理癫痫患者的癫痫发作。一些耐药性癫痫患者选择其他治疗方法,例如手术和植入大脑的装置以帮助控制癫痫发作。老年人口的增加增加了包括癫痫在内的神经系统疾病的患病率,同时市场上推出的产品也不断增加。政府为提高广大人口及其治疗意识而采取的举措激增,可能会在未来几年扩大癫痫药物市场的增长。
增长动力:
癫痫患病率的增加推动癫痫药物市场的增长
癫痫是一种以反复发作为特征的神经系统疾病。根据世界卫生组织2023年2月公布的数据,癫痫在全球疾病负担中占据很大份额,影响着全球近5000万人。预计在特定时间内患有活动性癫痫(即需要治疗或持续癫痫发作)的一般人群比例为每 1,000 人 4 至 10 人。
根据同一来源(世界卫生组织,2023 年 2 月) ),全世界每年有 500 万人被诊断患有癫痫症。据估计,高收入国家每年每 10 万人中有 49 人患有癫痫。在低收入和中等收入国家,这一数字可能高达每 10 万人 139 人。这可能是由于神经囊尾蚴病或疟疾等地方性疾病的高风险、与出生有关的伤害以及道路交通伤害的高发生率。大约 80% 的癫痫患者生活在低收入和中等收入国家。数据还表明,癫痫发作是可以控制的,大约 70% 的癫痫患者可以通过适当使用抗癫痫药物来消除癫痫发作。抗癫痫药物治疗是大多数癫痫患者的主要治疗方法。癫痫发作分类是设计治疗计划的关键因素,因为一些抗癫痫药物对不同类型的癫痫发作具有不同的作用。
因此,全球范围内癫痫患病率和发病率不断上升,导致癫痫药物的需求增加。
然而,产品召回会对公司业绩产生不利影响,降低品牌资产,引起消费者恐慌,损害公司声誉,导致收入和市场份额损失,并导致大量产品退货。近年来,癫痫药物市场发生多起产品召回事件,对市场增长产生负面影响。以下是最近的一些召回:
2023 年 7 月,赛诺菲英国公司因在氨己烯酸原料中检测到微量硫必利而召回了几批 Sabril 片剂和 Sabril 颗粒剂,作为预防措施。 Sabril(氨己烯酸)用作治疗婴儿痉挛症(韦斯特综合征)的单一疗法,并作为局灶性癫痫发作的佐剂,用于治疗局灶性癫痫发作,无论是否伴有随后的全身性癫痫发作,且其他抗癫痫药不能很好地控制(在专业监督下)。2023 年 7 月,Sun根据美国食品和药物管理局 (US FDA) 执法报告,Pharmaceutical Industries Inc. 因检测过程中不符合杂质标准而召回了近 9,000 瓶盐酸噻加宾片剂。 2021 年 11 月,Sagent Pharmaceuticals, Inc. 宣布主动召回四批左乙拉西坦注射液,USP,全国范围内的用户级别。储备样品瓶发现容器密封不完整,这可能导致产品非无菌。 2020 年 1 月,Taro Pharmaceuticals USA, Inc. 于 2 月在全国范围内自愿召回拉莫三嗪片 USP,100 毫克,100 瓶2020 年 2 月 20 日。该批次被发现与同一生产工厂用于生产其他不同产品的少量另一种药物(马来酸依那普利)交叉污染。拉莫三嗪 100 mg 片剂用于治疗癫痫和双相情感障碍。根据美国 FDA 2023 年 7 月 21 日更新的召回信息,Aurobindo Pharma 召回了 48 瓶 200 g 和 400 g 卢非酰胺片剂。此次召回是自愿的。卢非酰胺用于控制 Lennox-Gastaut 综合征患者的癫痫发作,这是一种严重的癫痫形式。因此,近期产品召回数量的增加阻碍了癫痫药物市场的增长。
战略见解
报告细分和范围:
“癫痫药物市场”根据治疗、分销渠道和地理位置进行细分。癫痫药物市场按治疗方法分为第一代抗癫痫药、第二代抗癫痫药和第三代抗癫痫药。 2022年,第二代抗癫痫药物占据最大市场份额;第三代抗癫痫药物预计在 2022 年至 2030 年期间复合年增长率最快。根据分销渠道,癫痫药物市场分为医院药房、零售药店等。 2022 年,医院药房领域占据最大的市场份额,零售药房领域预计在 2022 年至 2030 年期间复合年增长率最快。
细分分析:
癫痫药物市场按治疗方法细分为第一代抗癫痫药、第二代抗癫痫药、第三代抗癫痫药。 2022年,第二代抗癫痫药物占据最大市场份额;第三代抗癫痫药预计在 2022 年至 2030 年期间复合年增长率最快。第二代AED包括非氨酯、加巴喷丁、拉莫三嗪、左乙拉西坦、奥卡西平、普加巴林、卢非酰胺、司替喷醇、噻加宾、托吡酯、托吡酯、氨己烯酸和唑尼沙胺。在北美和欧洲,ZNS也被认为是第二代药物。与第一代药物相比,第二代 AED 的成本较高,这是限制其在处方集中提及的一个重要因素。与第一代药物相比,第二代 AED 具有更有利的副作用和更低的致畸风险。许多第一代和一些第二代 (AED) 具有酶诱导的共同特征,可以增加细胞色素 p450 酶靶向的不同底物的代谢,同时减少诱导剂的作用。
癫痫药物市场,按治疗方法 - 2022年和2030年
根据分销渠道,癫痫药物市场分为医院药房、零售药店等。 2022年,医院药房细分市场占据最大市场份额;零售药房领域预计在 2022 年至 2030 年期间复合年增长率最快。医院药房从不同公司采购药品,供应给医院用于门诊或住院治疗。医院药房通常提供适用于心脏病学、神经学、泌尿学、病理学、血液学和皮肤科的治疗和重症监护药物。医院药房是任何国家医疗保健系统的重要组成部分之一。这些药房备有癫痫药物库存,以确保患者随时可用。因此,医院药房占据了相当大的癫痫药物市场规模。
区域分析 - 癫痫药物市场:
根据地理位置,癫痫药物市场分为五个关键区域:北美、欧洲、亚太地区、南美洲和中美洲以及中东和非洲。 2022年,北美占据癫痫药物市场最大份额。预计 2022 年至 2030 年,亚太地区的全球癫痫药物市场复合年增长率最高。
亚太地区癫痫药物市场分为中国、日本、印度、韩国、澳大利亚和亚太其他地区。该地区癫痫药物市场的增长广泛受到癫痫患病率不断上升以及政府为增加发展中经济体大量人口而采取的举措激增的推动。预计中国将占据主要市场份额,而印度预计复合年增长率最高。 2019 年,印度癫痫患病率为每 1000 人 3 例至 12 例,其中农村人口发病率很高。由于知识和实践的巨大差距,印度大多数癫痫患者没有得到适当的治疗,导致治疗缺口。大约三分之一的癫痫患者患有耐药性癫痫。一项研究表明,癫痫在30-50岁的患者中很常见,其中男性占多数。局灶性癫痫在印度更为普遍。左乙拉西坦和丙戊酸分别是治疗局灶性癫痫和全身性癫痫最常用的 AED。
此外,药物开发正在推动该国癫痫药物市场的增长。例如,2021年3月,Alkem Laboratories宣布在印度推出用于治疗癫痫的平价抗癫痫药物Brivasure,创新产品Brivaracetam的专利已于2021年2月21日到期。Brivasure已获得药物管制员的批准印度将军(DCGI)。该药物表现出更快的起效和良好的安全性。因此,由于上述因素,癫痫药物市场可能会有效增长。
中国作为世界上人口最多的国家,也是神经系统疾病患者最多的国家之一。据疾病预防控制中心统计,我国活动性癫痫患病率为0.48%~8.5%;中国大陆约有900万癫痫患者,其中三分之二是儿童。约 30% 的癫痫患者无法使用目前市场上出售的 AED 控制癫痫发作;因此,这种疾病有大量未满足的医疗需求。
此外,该国的药物批准正在推动市场增长。例如,2021年8月,卫材株式会社获得了抗癫痫药物(AED)Fycompa的两项额外批准,作为“部分性癫痫发作的单一疗法”和“部分性癫痫发作的儿科适应症的辅助治疗/单一疗法”。国家药品监督管理局在中国批准了“四岁及以上癫痫患者的癫痫发作”。
Fycompa 已在中国获得批准,用于治疗伴有或不伴有继发性全身性癫痫发作的部分性癫痫患者的辅助治疗。 12 岁及以上患有癫痫症。通过此次批准,Fycompa 现已在中国作为单一疗法和辅助治疗用于治疗四岁及以上癫痫患者的部分性癫痫发作(伴或不伴继发性全身性癫痫发作)。中国癫痫药物市场的增长主要归因于癫痫病例的增加以及市场参与者开发癫痫药物的不断发展。
行业发展 - 癫痫药物市场:
领先企业采取的各种举措癫痫药物市场情况如下:
2023年10月,诺华通过向诺华股票和美国存托凭证持有人进行实物股息分配,完成了山德士的分拆。截至 2023 年 10 月 3 日收盘时,每位持有人每持有 5 股诺华股票即可获得 1 股山德士股票。山德士的分拆使诺华完成了转型,使其专注于一家药品公司。2023 年 9 月,赛诺菲出售了Pharmanovia 是一家在英国成立的公司,其产品组合中有 11 个与中枢神经系统相关的品牌,包括癫痫药物 Gardenal 和 Frisium。除了治疗其他药物治疗无效的患者的焦虑和精神病问题的 Tercian 之外,赛诺菲还放弃了癫痫药物 Gardenal 以及恶心和眩晕药物 Stemetil。 2023 年 1 月,辉瑞公司扩大了对“健康世界协议”的承诺。 《健康世界协议》是一项于 2022 年 5 月发起的倡议,旨在减少许多低收入国家与世界其他地区之间存在的健康不平等现象。辉瑞公司将为 45 个低收入国家的 12 亿人提供完整的药物和疫苗产品组合。 2023 年 1 月,Catalyst Pharmaceuticals Inc 从卫材有限公司(卫材)收购了 FYCOMPA(吡仑帕奈)CIII 在美国的权利。此次收购使 Catalyst Pharmaceuticals Inc 能够扩大美国在神经病学领域的商业影响力。它还通过成熟的、一流的、商业阶段的癫痫资产帮助扩大了产品组合。 2022 年 1 月,UCB 以 19 亿美元收购了 Zogenix,旨在通过增加 Fintepla 来增强其癫痫产品组合(芬氟拉明),一种上市药物,用于治疗与 Dravet 综合征(一种罕见的儿童癫痫)相关的癫痫发作。竞争格局和主要公司 - 癫痫药物市场:
UCB SA、诺华公司、辉瑞公司、葛兰素史克公司、雅培Laboratories、赛诺菲 SA、住友制药公司、梯瓦制药工业有限公司、Catalyst Pharmaceuticals Inc 和 Alkem Laboratories Ltd 都是癫痫药物市场上的知名公司。这些公司专注于新技术、现有产品的进步和地域扩张,以满足全球不断增长的消费者需求。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which region is dominating the epilepsy drugs market?

North America region is dominating the epilepsy drugs market in terms of market share and Asia Pacific is anticipated to register the highest CAGR during the forecast period.

Which segment is dominating the epilepsy drugs market?

The epilepsy drugs market is analyzed on the basis of treatment and distribution channel. Based on treatment, the market is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. Based on distribution channel, the market is classified as hospital pharmacy, retail pharmacy stores, and others.

Who are the major players in the epilepsy drugs market?

The epilepsy drugs devices market majorly consists of the players such as UCB SA, Novartis AG, Pfizer Inc, GSK Plc, Abbott Laboratories, Sanofi SA, Sumitomo Pharma company, Teva Pharmaceutical Industries Ltd, Catalyst Pharmaceuticals Inc, and Alkem Laboratories Ltd.

What are the driving factors for the global epilepsy drugs market worldwide?

The growth of the global epilepsy drugs market is attributed to a few key factors, such as Increasing prevalence of epilepsy and increasing number of elderly populations.

What are epilepsy drugs?

Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic drugs (AEDs), which are commonly used for the treatment of epilepsy as it helps in the better management of seizures among epilepsy patients. Some of the patients with drugs resistance epilepsy opt for other treatment methods such as surgery and devices that are implanted in the brain to helps in seizure management.

The List of Companies - Epilepsy Drugs Market 

  1. UCB SA
  2. Novartis AG
  3. Pfizer Inc
  4. GSK Plc
  5. Abbott Laboratories
  6. Sanofi SA
  7. Sumitomo Pharma company
  8. Teva Pharmaceutical Industries Ltd
  9. Catalyst Pharmaceuticals Inc
  10. Alkem Laboratories Ltd

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports